JP2004501650A5 - - Google Patents

Info

Publication number

JP2004501650A5

JP2004501650A5 JP2002506221A JP2002506221A JP2004501650A5 JP 2004501650 A5 JP2004501650 A5 JP 2004501650A5 JP 2002506221 A JP2002506221 A JP 2002506221A JP 2002506221 A JP2002506221 A JP 2002506221A JP 2004501650 A5 JP2004501650 A5 JP 2004501650A5

Authority

JP

Japan

Prior art keywords

adenovirus

vector according

region

adenovirus vector

genome

Prior art date

2001-06-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 241000701161 unidentified adenovirus Species 0.000 description 80
• 239000013598 vector Substances 0.000 description 48
• 102100040247 Tumor necrosis factor Human genes 0.000 description 16
• 108091028043 Nucleic acid sequence Proteins 0.000 description 12
• 150000007523 nucleic acids Chemical group 0.000 description 12
• 125000006850 spacer group Chemical group 0.000 description 11
• 125000000539 amino acid group Chemical group 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 5
• 238000004519 manufacturing process Methods 0.000 description 5
• 241000700605 Viruses Species 0.000 description 4
• 230000002950 deficient Effects 0.000 description 4
• 230000008488 polyadenylation Effects 0.000 description 4
• 230000005855 radiation Effects 0.000 description 4
• 239000004475 Arginine Substances 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• 101710145505 Fiber protein Proteins 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 238000000034 method Methods 0.000 description 3
• 239000000203 mixture Substances 0.000 description 3
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 101100444898 Mus musculus Egr1 gene Proteins 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 239000008194 pharmaceutical composition Substances 0.000 description 2
• 230000005030 transcription termination Effects 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000012830 cancer therapeutic Substances 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1